Abstract: Because sildenafi l citrate is a treatment, not a cure, for erectile dysfunction (ED), many men may choose to use it for an extended period. Men with ED who had previously completed 1 of 4 double-blind trials with short-term open-label extension (combined duration, 0.9-1.2 years) were eligible for this 4-year, open-label, extension study, which assessed the safety and effectiveness of fl exible doses (25, 50, and 100 mg sildenafi l) used as needed. Adverse events that were serious or led to dosing changes or discontinuation (temporary or permanent) were recorded. Many of the 979 participants (mean age, 58 [range, 27-82] years; mean ED duration, 4.5 years) had concomitant hypertension (28%), diabetes (22%), or hyperlipidemia (14%). Overall, 37 (3.8%) had treatment-related adverse events (none serious) requiring dosage change or discontinuation and 62 (6.3%) discontinued because of insuffi cient response. At each yearly assessment, more than 94% of participants responded affi rmatively to the questions: "Are you satisfi ed with the effect of treatment on your erections?" and "If yes, has treatment improved your ability to engage in sexual activity?" These results argue against the loss of tolerability or the development of tachyphylaxis over a prolonged period of as needed, fl exible-dose sildenafi l treatment of men with ED.
Introduction
In March 1998, the US Food and Drug Administration (FDA) approved sildenafi l citrate (Viagra ® , Pfi zer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998) . As of December 2005, more than 27 million men worldwide had received sildenafi l for treatment of ED, including an estimated 17 million men in the US (Data on fi le, Pfi zer Inc, New York, NY). Thus, the long-term safety and effectiveness of sildenafi l can now be evaluated in men who have been taking the drug for several years.
The effi cacy, safety, and tolerability of sildenafi l in the treatment of men with ED have been demonstrated in numerous studies of 1-year duration or less. For example, 1,358 men with ED completed 1 of 4 double-blind trials and continued with open-label sildenafi l treatment in extension studies for a total treatment duration of approximately 1 year (Morales et al 1998; Steers et al 2001) . In the current study, 979 of these men subsequently received up to 4 more years of open-label, fl exible-dose (25, 50, and 100 mg) sildenafi l. Preliminary (3-year) results were reported previously (Carson et al 2002; Padma-Nathan et al 2002) , and we now present the fi nal data. The population included patients with ED of organic and psychogenic etiology and typical concomitant medical conditions for this population (ie, hypertension, diabetes, hyperlipidemia, and a history of ischemic heart disease). Our objective was to assess the long-term safety and effectiveness of sildenafi l treatment in men with ED.
Methods
This was a 4-year, open-label, fl exible-dose (25, 50, and 100 mg) study of sildenafi l. Men who previously completed and were compliant with sildenafi l or placebo treatment in 1 of 4 double-blind, placebo-controlled trials, and subsequently completed and were compliant with sildenafi l treatment in initial open-label extension, were eligible for inclusion in this long-term extension study. Study medication was provided at no cost. Compliance was assessed by medication diaries and by continued study participation.
A total of 1,545 men were originally enrolled in the double-blind trials, with 1,358 of these men continuing in the initial open-label extension studies. The current study includes 979 of the original patients, who agreed to participate in the long-term extension (Figure 1 ). The procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional).
At the time the study started, the FDA stated that there were suffi cient routine safety data on sildenafi l to make collection of standard adverse event data unnecessary. Therefore, only serious adverse events and adverse events leading to changes in dosing or to temporary or permanent discontinuation were recorded and evaluated by the investigators for relatedness to sildenafi l treatment.
Because the major focus of this study was safety, and it was designed before the development and validation of patientreported outcomes to assess satisfaction with the quality of erection (eg, Quality of Erection Questionnaire (Porst et al 2007) ) or satisfaction with ED treatment (eg, the Erectile Dysfunction Inventory of Treatment Satisfaction (Althof et al 1999) ), effectiveness was assessed by asking, at yearly intervals or at discontinuation, simple, unvalidated general effi cacy questions, "Are you satisfi ed with the effect of treatment on your erections?" and "If yes, has treatment improved your ability to engage in sexual activity?" The second question was based on the ED defi nition of the National Institutes of Health Consensus Conference: "…inability to attain and/or maintain penile erection suffi cient for satisfactory sexual performance." (NIH Consensus Conference. Impotence. (25, 50 , and 100 mg) sildenafi l long-term extension study. Of the 979 participants who entered the sildenafi l long-term extension study, 584 (60%) completed all 4 years. Reasons for discontinuation, other than insuffi cient clinical response and treatment-related adverse event (AE), included AE unrelated to treatment, protocol violation, loss to follow-up, and other (eg, loss of interest in participation in a clinical study, loss of sexual partner, and ability to afford sildenafi l after approval [thus, no longer needing to participate in a clinical study to obtain the medication]). N for the satisfaction question ("Are you satisfi ed with the effect of treatment on your erections?") is equal to the number of men who answered. *Some of the discontinued subjects supplied satisfaction data.
Sildenafi l long-term treatment NIH Consensus Development Panel on Impotence 1993). Descriptive statistics were calculated.
Results
Overall, 979 men initially agreed to participate in the study, most of whom were white (89%) and whose mean age was 58 years (Table 1 ). The duration of the double-blind trials plus initial open-label extension was 0.9 to 1.2 years (48-60 weeks). Median duration of participation in the openlabel, long-term extension study was 4 years, the median number of doses taken was 420 (range, 1-1469) (Figure 2 ), and the preferred dose was 100 mg in more than 88% of the men. The retention rate was 84% (818/979) the fi rst year, 75% (731/979) the second year, and 66% (648/979) the third year; the entire 4-year extension study was completed by 584 of the initial 979 men (60%) (Figure 1 ). Reasons for discontinuation included loss of interest in participation in a clinical study, loss of sexual partner, loss to follow-up, ability to afford sildenafi l after approval (thus, no longer needing to participate in a clinical study to obtain the medication), insuffi cient clinical response, and adverse events.
Tolerability
Over the 4-year study period, 37 (3.8%) of the men had 1 or more adverse events that led to changes in dosing or to temporary or permanent discontinuation and were determined by the investigators to be treatment-related (Table 2) . Of the 47 events, headache and dyspepsia were most common (n = 10 each), followed by rhinitis (n = 6), fl ushing (n = 5), abnormal vision (n = 4), dizziness (n = 3), and 1 report each of mild palpitations, moderate tachycardia, diarrhea, nausea, myalgia, hypertonia, respiratory disorder, conjunctivitis, and photophobia. Of the few cardiovascular events determined by the investigator to be treatment related (4 cases of mild fl ushing and 1 each of moderate fl ushing, mild palpitations, and moderate tachycardia), only 1 led to permanent discontinuation. In this case the man experienced mild fl ushing with the fi rst dose of sildenafi l 100 mg but continued therapy after a dose reduction. After 629 days of therapy, at which time his dosage was once again 100 mg, he permanently discontinued sildenafi l because of the fl ushing. Two other cardiovascular events led to temporary discontinuation (mild fl ushing and moderate tachycardia), and the remainder were addressed with a change in dosing. Of the 149 serious adverse events that occurred during the 4 years of the study, including 18 acute myocardial infarctions, none were considered by the investigator to be treatment related.
Each treatment year, less than 1% of the men who started the year discontinued sildenafi l because of treatment-related adverse events, for a total of only 11 (1.1%) of the original 979 participants over the 4 years of the study (Table 3) . Discontinuations were caused by dyspepsia (n = 4), rhinitis (n = 2), abnormal vision plus headache (n = 1), dyspepsia plus rhinitis (n = 1), and fl ushing, dizziness, and myalgia (n = 1 each).
Effectiveness
Of the 979 men who participated in the study, 932 (95%) were analyzed for effi cacy. At the completion of each year, at least 94% of the annually decreasing number of participants reported satisfaction with the effect of sildenafi l treatment on their erections, with only a 3.3 percentage point variation across the 4 yearly assessments (Table 4) . Almost all of these men reported improved ability to engage in sexual activity.
Each treatment year, less than 3% of the men who started the year discontinued sildenafi l treatment because of insuffi cient clinical response. Over the 4 years of the study, only 62 (6.3%) of the original 979 participants discontinued because of insuffi cient response (Table 3) .
Discussion
There are numerous data published on the effi cacy and safety of sildenafi l treatment for ED. Before approval, sildenafi l was evaluated in 18 phase II/III double-blind, placebo-controlled trials, in which men with ED were randomized to receive treatment with sildenafi l (n = 2722) or placebo (n = 1552) for up to 6 months (Morales et al 1998) . Pooled data from these trials demonstrated that sildenafi l is a well-tolerated oral therapy for ED (Morales et al 1998) . Adverse events were mostly transient and mild to moderate in severity and included most commonly headache, fl ushing, dyspepsia, and rhinitis. The rate of discontinuation because of adverse events Other treatment-related AEs were abnormal vision (n = 4), dizziness (n = 3), and 1 report each of mild palpitations, moderate tachycardia, diarrhea, nausea, myalgia, hypertonia, respiratory disorder, conjunctivitis, and photophobia. b Because serious adverse events are collected for a longer period (30 days after the completion of treatment) than adverse events in general, numbers of events may vary between these 2 databases.
from 11 double-blind, fl exible-dose, placebo-controlled trials that included a total of 2,667 men ages 23 to 89 years with ED of broad-spectrum etiology show signifi cantly improved erectile function for sildenafi l compared with placebo as measured by the International Index of Erectile Function, a global effi cacy question, and a patient-recorded event log of sexual activity (Carson et al 2002) .
The population of the current 4-year open-label study of sildenafi l differed from those of the pooled double-blind studies in that it was self-selected. Consequently, it is likely that men with poor tolerability or inadequate effectiveness did not opt to participate and that the population included mostly men who had previously experienced a good response to sildenafi l. Also, men who could afford to purchase sildenafi l may have lost incentive to participate in the long-term study when sildenafi l became commercially available. This phenomenon necessitated discontinuation of a European long-term OL study when sildenafi l became commercially availabile in Europe (Padma-Nathan et al 2001). Another limitation was the use of unvalidated general effi cacy questions, explained by the fact that the major focus of the study was safety and by the absence at the time of the study design of appropriate validated questionnaires to assess satisfaction with ED treatment. Regardless, the results add to the previously published reports by showing continued safety and effectiveness during prolonged treatment. During 4 years of open-label, fl exibledose administration, there were few discontinuations because of either intolerable adverse events or insuffi cient clinical response. The majority of men were satisfi ed with sildenafi l treatment for their ED and reported improved ability to engage in sexual activity. Throughout the 4-year study period, the consistently low incidence of adverse events of suffi cient severity to negatively impact treatment argues against the loss of tolerability with time, and the low rate of discontinuation because of insuffi cient clinical response (Ͻ3% per year) argues against the development of tachyphylaxis. The broad usage range (1-1469 doses over 4 years) demonstrates the "real world" experience provided by the study.
Despite a preferred sildenafi l dose of 100 mg (the highest recommended dose) in more than 88% of the men, treatmentrelated cardiovascular adverse events necessitating changes in dosing or temporary or permanent discontinuation were limited to one case each of mild palpitations and tachycardia and 5 cases of fl ushing. There were no treatment-related acute myocardial infarctions or other serious adverse events. Only 1.1% of participants discontinued treatment over 4 years because of treatment-related adverse events, which were most frequently dyspepsia, rhinitis, and headache. In comparison, treatment-related adverse events were responsible for discontinuation by 1.2% of men treated with sildenafi l 100 mg in 6-month, double-blind, placebo-controlled trials (Morales et al 1998) and by 2% of 1008 men enrolled in 36-week or 52-week, open-label extension studies (Steers et al 2001) . Adverse events were responsible for similarly low rates of discontinuation in clinical practice studies of varying duration conducted worldwide; in California 2.7% of 74 men discontinued (Marks et al 1999) , in Brazil none of 256 men discontinued (Moreira et al 2000) , and in China none of 1,290 men discontinued (Jiann et al 2003) . Among 22,471 men treated with sildenafi l in general practice in the UK, headache was the most frequently reported treatment-related adverse event and was cited as the reason for discontinuation in 0.3% of men (Boshier et al 2004) . For the satisfaction analyses, N is equal to the number of men who answered the satisfaction question. For the respective sexual activity analyses, N is equal to the number of men who answered the satisfaction question affi rmatively and answered the sexual activity question.
The satisfaction with the effectiveness of sildenafi l for the treatment of ED that was reported in the current study confi rms previous results. In one multicenter, open-label study, 176 men with ED completed the validated Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire after long-term successful intracavernosal prostaglandin E 1 and again 12 weeks after switching to fl exible-dose oral sildenafi l (25, 50, and 100 mg) (Montorsi et al 2003) . Sildenafi l treatment was associated with significantly greater overall treatment satisfaction, ease of use, and intention to continue treatment. Moreover, partners were more satisfi ed with sildenafi l overall, and their responses correlated with the satisfaction of the patients. Other wellcontrolled studies using EDITS have shown similarly high degrees of satisfaction with sildenafi l (Eardley et al 2004; Lewis et al 2001) .
Conclusions
In this 4-year, open-label study, there was a low incidence of adverse events that resulted in dosage change or discontinuation, and most continuing participants were satisfi ed with sildenafi l treatment for their ED. These data are consistent with previous reports and argue against loss of tolerability or development of tachyphylaxis.
